Novo Nordisk ranks 4th among the world's top 20 science employers

Novo NordiskNovo Nordisk was just ranked number four on the Science 2012 Top Employer list - up from ninth place last year. The company's 'social responsibility', 'respect for employees' and ability to inspire 'loyalty among its employees' were cited as key drivers of this impressive global ranking.

"We're proud to have jumped to the top five in this widely-recognised ranking of the world's best science employers. Our excellent researchers around the world are the main source of this company's strong innovation. The fact that they feel respected and take pride in working for a company that operates in a sustainable way is great to see. In the battle to recruit the best researchers, there's nothing more powerful than peer-to-peer communication," says Mads Krogsgaard Thomsen, chief science officer and executive vice president at Novo Nordisk.

R&D professionals at Novo Nordisk comprise world-class experts in the engineering, expression, formulation and delivery of therapeutic proteins, as well as in the development of compounds into safe, effective and convenient treatment options for people living with chronic conditions like diabetes, haemophilia and rheumatoid arthritis. More than 4,000 employees work in Novo Nordisk R&D in Denmark, US, China and India.

"This positive evaluation of Novo Nordisk resonates well with my own personal experience as a diabetes researcher in the company for the past 21 years. Our collaborative work in multidisciplinary teams both within and outside of the company, and our openness to explore new ideas inspire me. It gives me the confidence that I'm part of a highly-qualified team working every day to find better treatment solutions for people with diabetes," says Erica Nishimura, scientific director of Diabetes Biology at Novo Nordisk.

In the Science 2012 survey, 4,276 employees working in the biotechnology, biopharmaceutical, pharmaceutical and related industries were asked to rank the 20 best employers based on 23 characteristics, including research-driven environment and financial strength.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Most Popular Now

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Novartis and Microsoft announce collaboration to t…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science pa...

Ian Read to retire as Executive Chairman of Pfizer…

Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to...

FDA approves first oral GLP-1 treatment for type 2…

The U.S. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along w...

Discovery of new source of cancer antigens may exp…

For more than a decade, scientist Stephen Albert Johnston and his team at Arizona State University's Biodesign Institute have pooled their energies into an often scoffed-...

Chinese activists protest the use of traditional t…

In the West, the number of people challenging scientific authority has been growing in past decades. This has, among other things, led to a decline in the support for mas...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Dengue virus becoming resistant to vaccines and th…

Researchers from Duke-NUS Medical School (DukeNUS), in collaboration with the Agency for Science, Technology and Research (A*STAR)'s Bioinformatics Institute (BII), and t...